Schafer Cullen Capital Management’s Novartis NVS Stock Holding History

Schafer Cullen Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$12.8M	Sell	150,035 -1,942,995	-93%	-$174M	2.61%	11
2020 Q4	$198M	Sell	2,093,030 -154,119	-7%	-$13.5M	2.93%	1
2020 Q3	$195M	Sell	2,247,149 -78,935	-3%	-$6.84M	3.07%	1
2020 Q2	$203M	Sell	2,326,084 -137,195	-6%	-$11.8M	3.13%	1
2020 Q1	$203M	Sell	2,463,279 -128,085	-5%	-$11.4M	3.4%	1
2019 Q4	$245M	Sell	2,591,364 -81,549	-3%	-$7.32M	2.88%	1
2019 Q3	$232M	Sell	2,672,913 -103,348	-4%	-$9.28M	2.8%	1
2019 Q2	$245M	Buy	2,776,261 +273,201	+11%	+$23.1M	2.88%	1
2019 Q1	$216M	Sell	2,503,060 -169,786	-6%	-$13.6M	3.16%	1
2018 Q4	$206M	Sell	2,672,846 -229,652	-8%	-$17.9M	3.17%	1
2018 Q3	$224M	Buy	2,902,498 +29,661	+1%	+$2.19M	2.91%	1
2018 Q2	$194M	Sell	2,872,837 -119,821	-4%	-$8.27M	2.51%	2
2018 Q1	$217M	Buy	2,992,658 +50,817	+2%	+$3.87M	2.61%	1
2017 Q4	$221M	Sell	2,941,841 -8,831	-0.3%	-$666K	2.57%	1
2017 Q3	$227M	Sell	2,950,672 -152,484	-5%	-$11.5M	2.73%	1
2017 Q2	$232M	Buy	3,103,156 +260,354	+9%	+$18.5M	2.89%	1
2017 Q1	$189M	Buy	2,842,802 +236,617	+9%	+$15.8M	2.43%	2
2016 Q4	$170M	Buy	2,606,185 +1,029,648	+65%	+$66.8M	2.31%	3
2016 Q3	$112M	Buy	1,576,537 +73,654	+5%	+$5.37M	1.34%	34
2016 Q2	$111M	Buy	1,502,883 +18,399	+1%	+$1.27M	1.35%	33
2016 Q1	$96.4M	Sell	1,484,484 -38,744	-3%	-$2.64M	1.18%	41
2015 Q4	$117M	Sell	1,523,228 -215,208	-12%	-$17.1M	1.4%	31
2015 Q3	$143M	Sell	1,738,436 -24,388	-1%	-$2.17M	1.64%	21
2015 Q2	$155M	Sell	1,762,824 -96,942	-5%	-$8.89M	1.6%	24
2015 Q1	$164M	Buy	1,859,766 +653,939	+54%	+$58M	1.63%	24
2014 Q4	$100M	Sell	1,205,827 -825,117	-41%	-$68.4M	1.27%	34
2014 Q3	$171M	Buy	2,030,944 +6,019	+0.3%	+$487K	1.64%	22
2014 Q2	$164M	Sell	2,024,925 -17,508	-0.9%	-$1.38M	1.51%	27
2014 Q1	$156M	Buy	2,042,433 +140,973	+7%	+$10.3M	1.51%	28
2013 Q4	$137M	Buy	1,901,460 +195,750	+11%	+$13.6M	1.36%	31
2013 Q3	$117M	Buy	1,705,710 +242,649	+17%	+$16.1M	1.29%	34
2013 Q2	$92.7M	Buy	+1,463,061	New	+$95.2M	1.11%	34

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.7B AUM 13.92% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Schafer Cullen Capital Management's NVS Position: Q1 2021 in Review

Schafer Cullen Capital Management reduced its Novartis (NVS) stake by 93% in Q1 2021, selling an estimated $174M and leaving 150,035 shares worth $12.8M. The position accounts for 2.61% of the portfolio, ranked #11.

Schafer Cullen Capital Management first reported a position in NVS in Q2 2013 and has held it in 32 quarters since. The position peaked at $245M in Q4 2019. 1,136 funds tracked by Wall St. Rank hold NVS as of Q1 2021.

Schafer Cullen Capital Management held 150,035 shares of Novartis worth $12.8M as of Q1 2021.
Schafer Cullen Capital Management sold 1,942,995 Novartis shares in Q1 2021, an estimated $174M.
Novartis made up 2.61% of Schafer Cullen Capital Management's portfolio in Q1 2021, its #11 holding.
Schafer Cullen Capital Management first reported a position in Novartis in Q2 2013 and has held it in 32 quarters since.
Schafer Cullen Capital Management's Novartis position peaked at $245M in Q4 2019.
1,136 funds tracked by Wall St. Rank held Novartis as of Q1 2021.

Based on Schafer Cullen Capital Management's 13F filing for Q1 2021, filed 10 May 2021.